亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢楷倫公司銷售部  

埃索美拉唑,埃索美拉唑鎂三水合物,5-甲氧基-2-巰基-1H-苯并咪唑,頭孢雷特,普格拉雷等

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:童瑤
  • 電話:027-88395717
  • 郵件:kailun002@126.com
  • 傳真:027-88735683
  • QQ:2524490512
站內搜索
 
榮譽資質
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 121659-86-7匹伐他汀鈣中間體的廠家
121659-86-7匹伐他汀鈣中間體的廠家
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
品牌 121659-86-7
型號 121659-86-7
規格 121659-86-7
過期 長期有效
更新 2013-09-26 11:11
 
詳細信息
CAS號121659-86-7匹伐他汀鈣中間體
121659-86-7匹伐他汀鈣中間體的廠家
CAS號121659-86-7匹伐他汀鈣中間體中文名:2-環丙基-4-(4-氟苯基)-3-喹啉羧酸甲酯
英文名:Methyl 2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylate
分子式:C20H16FNO2
分子量:321.34
CAS:121659-86-7
質量標準:企業標準
含量 ≥98.0%
性狀 黃色結晶
干燥失重 ≤1.0%
用途:121659-86-7是匹伐他汀鈣中間體
包裝:1-5公斤/包,25公斤/桶
©2025 武漢楷倫公司銷售部 版權所有   技術支持:化工網   訪問量:10693  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |